10:15 am – 11:00 am – How Much is Right for You: The Science of CBD Dosing
One of the challenges in the emerging CBD market is the lack of robust clinical research that can be used to guide dosing guidelines. This is especially problematic in people with comorbidities or on other medications who would like to explore taking these products medicinally too. Even so, crowdsourcing the anecdotal data has allowed companies to review by developing a functional measure of how much CBD is needed for different conditions. This system, albeit lacking in strong foundations in clinical trials, in some ways is good enough. But when it comes to a product we want to promote as medication, we have a responsibility to produce real data from which to work off of.
11:15 am – 12:00 pm – So, You Think You Can CBD…
(Hemp Derived vs Cannabis Derived CBD and Full Spectrum vs. Broad Spectrum vs. Isolate)
In today’s early stages of the legal hemp marketplace, there are thousands of CBD products available, yet not much in the way of differentiation – at least not knowingly in most cases. All legitimate CBD products contain at least some amount of cannabidiol, but they may also contain (or specifically not contain) other elements, depending on how they’re labeled. In this panel, we examine and specifically define the terms relating to this phenomenon: hemp-derived, cannabis-derived, full-spectrum, broad-spectrum, CBD isolate, and more.
12:00 pm – 12:30 pm – LUNCH BREAK
12:30 pm – 1:15 pm – Get the 411 on Cannabinoid Pharmacology 101
Cannabinoids are wonderful compounds with one very big problem–they are lipophilic, or fat loving. This makes dosing very, very tricky. And why it’s so hard to measure cannabinoid levels in the blood and urine. The pharmacokinetics and pharmacodynamics of cannabinoids are greatly affected by various factors, such as the amount and type of food eaten in a given day, whether other substances, including medications, were taken, and how they were consumed (vape, oil, edible, etc.). For these reasons and more, despite decades of research, the best advice to offer new users remains the “start low, go slow” method, which is as unscientific as it comes. And explains why this topic remains red hot in research.
1:30 pm – 2:15 pm – Creating Novel CBD Formulations and Blends
While scores of people may benefit from CBD isolates, many more have reported respite from their ailments using full-spectrum products that contain many more of the natural molecules native to hemp, like other cannabinoids and terpenes. Still yet, many product manufacturers are looking to design novel formulations that incorporate some of these molecules, without necessarily being considered as “full-spectrum”. These products may contain other minor cannabinoids and terpenes, but the inclusion of these ingredients are done with purposeful intent, such as creating products designed as sleep aids, or for treatment of pain or anxiety. Additionally, blending these formulations with other dietary supplements such as ginseng or melatonin can present an exciting new product line that combine traditional supplements with the surging interest in hemp-derived molecules, thereby presenting the best of both worlds. This panel will help you understand what types of products are currently in demand, and will illustrate how the rapidly evolving CBD industry is changing.
2:30 pm – 3:15 pm – Psychedelics & Cannabinoid Therapeutics: What Does the Future Hold?
Alongside the CBD boom, the functional Mushroom market has experienced a profound amount of growth with certain estimates putting market growth upwards of $35 Billion. Similarly situated to cannabis treatments as both controversial and poorly understood, there remains tremendous potential on the horizon for mycelia like Cordycepin and Psilocybin. As consumers look to herbal treatments for an assortment of ailments and quality of life improves the future of hemp products and mushrooms while regulations take shape the question remains whether or not there is a future for CBD and Mushrooms.